Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=356 Orthostatic Hypotension Treatment on Rehab Unit
Orthostatic Hypotension · Falls
Primary: Orthostatic Hypotension at Discharge — 39; 44 Participants — p=0.6
Phase 2 N=109 Sex Hormones and Orthostatic Tolerance
Orthostatic Intolerance
Primary: Orthostatic Tolerance — 634 mmHg*min
N/A N=341 Orthostatic Hypotension in Rehabilitation Patients
Hypotension, Orthostatic
Primary: Orthostatic Hypotension at Discharge — 96 participants
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Phase 4 N=98 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
Phase 4 N=140 A Study for Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale — 4.1; 5.2 scores on a scale — p=<0.001
Phase 3 N=66 Treatment of Post-SCI Hypotension
Spinal Cord Injury · Autonomic Dysreflexia · Orthostatic Hypotension
Primary: Affected Therapy Sessions — 16.4; 10.9 percentage of sessions
Phase 4 N=24 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Orthostatic Hypotension
Primary: Time to Onset of Syncope/Near Syncope While on Tilt Table — 1105.6; 1626.6 seconds — p=0.0131
Phase 2 N=85 Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension
Intradialytic Hypotension
Primary: Change in Average Mean Arterial Blood Pressure During Hemodialysis — -0.12; 1.95; 1.60 mmHg — p=0.693
Phase 4 N=24 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460
Phase 2 N=10 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Hypotension, Postural
Primary: Systolic Blood Pressure — 97; 103; 90; 88 mm Hg
Phase 2 N=21 The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Spinal Cord Injury · Autonomic Dysreflexia · Baroreceptor Integrity
Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg
Phase 2 N=11 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
Orthostatic Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
N/A N=20 Nebivolol in the Supine Hypertension of Autonomic Failure
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure During the Night — 154; 162; 157; 158 mm Hg — p=0.036
Phase 2 N=34 TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Neurogenic Orthostatic Hypotension · Multiple System Atrophy (MSA) With Orthostatic Hypotension · Pure Autonomic Failure
Primary: Part A: Change From Time-matched Placebo in Seated Systolic Blood Pressure (SBP) — 0.2; -1.8; -3.4; -2.9 millimeter of mercury (mmHg)
N/A N=22 Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure — 19; 3 mm Hg
Phase 3 N=350 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Primary Autonomic Failure · Dopamine Beta Hydroxylase Deficiency · Non-Diabetic Neuropathy
Primary: Patients With Treatment-emergent Adverse Events — 263 participants
Phase 4 N=21 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
Hypotension, Orthostatic · Hypotension · Spinal Cord Injuries
Primary: Proportion of Systolic BP Within a Normotensive Range — 167; 117; 89 Systolic Blood Pressure Recordings
Phase 2 N=20 Using Mirabegron to Increase BP in Patients With POTS
Postural Orthostatic Tachycardia Syndrome · Chronic Orthostatic Intolerance · Syncope
Primary: Blood Pressure — 101; 107; 64; 68 mmHg
Phase 4 N=32 Angiotensin II in General Anesthesia
Hypertension
Primary: Median Dose Required to Increase the Systolic Blood Pressure (SBP) — 35; 43; 45 ng/kg/min
N/A N=214 Hypotension Prediction Index for Blood Pressure Management
Intraoperative Hypotension
Primary: Time- Weighted Average (TWA) MAP Under a Threshold of 65 mmHg. — 0.14; 0.14 mmHg — p=0.757
N/A N=12 Effect of Exercise in OI
Orthostatic Intolerance · Postural Tachycardia Syndrome
Primary: Maximal Oxygen Consumption Capacity (VO2 Max) — 27.6; 24.5 mL/kg/min
Phase 3 N=181 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Phase 2 N=47 Efficacy Study of a Facemask Device to Treat Hypotension
Hypotension
Primary: Rise in Systolic Blood Pressure Over the First 10 Minutes of Use Compared to Baseline — 5.9; 12.9 mm Hg
Phase 3 N=136 Midodrine for the Treatment of Refractory Hypotension
Hypotension · Critical Illness
Primary: Time Until Discontinuation of IV Vasopressors — 23.5; 22.5 hours
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 3 N=263 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
Phase 3 N=321 A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Catecholamine-resistant Hypotension (CRH) · Distributive Shock · High Output Shock
Primary: An Increased MAP, Defined as Achievement of a Day 1 MAP at 3 Hours Following the Initiation of Study Drug, of ≥ 75 mmHg OR a 10 mmHg Increase in Baseline MAP — 114; 37…